Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a pioneering developer of minimally invasive devices for treating venous thromboembolism and related vascular conditions. This page provides investors and healthcare professionals with essential updates on corporate developments, financial performance, and clinical advancements.
Access real-time announcements including quarterly earnings reports, FDA clearances, clinical trial data, and strategic partnerships. Our curated news feed ensures you stay informed about NARI's innovative thrombectomy technologies and market positioning within the interventional medical device sector.
Key updates include product launch details, regulatory milestones, peer-reviewed study publications, and executive leadership changes. All content is sourced directly from verified company communications and SEC filings to ensure accuracy.
Bookmark this page for streamlined access to Inari Medical's latest developments. For comprehensive analysis of how these updates may impact long-term growth strategies, consult your financial advisor.
Masimo (NASDAQ: MASI) has announced significant leadership changes effective February 12, 2025. Katie Szyman, currently worldwide president of Advanced Patient Monitoring at BD, has been appointed as the new CEO. Michelle Brennan, who served as Interim CEO, has been named Chairman of the Board, while Lead Independent Director Quentin Koffey becomes Vice Chairman.
Szyman brings over 35 years of experience, notably leading Edwards Lifesciences' Critical Care product group before its acquisition by BD in September 2024. Her appointment follows an extensive search process by Korn Ferry. The Board selected Szyman for her track record in accelerating revenue growth, experience in bringing new patient monitoring products to market, and success in leading industry talent.
The Board continues its previously announced strategic review of alternatives for both consumer audio and consumer healthcare businesses, with Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as legal advisor.
Inari Medical (NASDAQ: NARI), a medical device company focused on treating venous and vascular diseases, has announced its upcoming presentation at the J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15 at 8:15 a.m. Pacific Time.
The company has made arrangements for interested parties to access both a live webcast and replay of the presentation through Inari Medical's investor relations website. This presentation represents an important opportunity for the company to showcase its developments in venous and vascular disease treatment technologies.
Inari Medical (NASDAQ: NARI) has received national reimbursement approval from Japan's Ministry of Health, Labor and Welfare for its ClotTriever Thrombectomy System for DVT treatment. The system received a new functional category with a reimbursement premium based on clinical safety and efficacy data. Inari has partnered with Medikit Co., for distribution in Japan, planning to initiate a 100-patient Post Market Surveillance study followed by commercial expansion. The ClotTriever system has been used in over 75,000 procedures globally and has shown strong safety profile and low rates of post-thrombotic syndrome in recent two-year outcomes from the 500-patient ClotTriever CLOUT Registry.
Inari Medical (NASDAQ: NARI) has announced a strategic joint venture with 6 Dimensions Capital, its successor fund 120 Capital, and VFLO Medical to expand access to its medical technologies in Greater China. The partnership will enable Inari to commercialize its devices through VFLO's established infrastructure and local relationships. VFLO will have rights to manufacture Inari's products for domestic sale in Greater China, leveraging their commercial expertise and Inari's global strengths in venous thrombectomy product development and manufacturing.
Inari Medical (NASDAQ: NARI) has announced its participation in the upcoming Jefferies London Healthcare Conference. The medical device company's management team will deliver a presentation on Wednesday, November 20, 2024, at 10:00 AM GMT / 5:00 AM ET.
Interested parties can access a live audio webcast of the presentation through the company's website at www.inarimedical.com under the Investor Relations section. The presentation recording will remain available for replay for 30 days following the event.
Inari Medical announced positive results from the PEERLESS Randomized Controlled Trial comparing FlowTriever to catheter-directed thrombolytics (CDT) for intermediate-risk pulmonary embolism. The study, conducted across 57 centers with 550 patients, met its primary composite endpoint with a win ratio of 5.01 (p<0.001). FlowTriever demonstrated superiority with patients experiencing:
- 3X fewer clinical deteriorations and therapy escalations
- Fewer ICU admissions and shorter ICU stays
- Faster recovery of clinical symptoms
- Shorter hospital stays
- Fewer 30-day readmissions
The FlowTriever arm showed excellent safety with zero patient deaths at discharge or 7 days, no cardiac arrest-related deteriorations, and 0.4% all-cause mortality at 30-day follow-up.
Inari Medical reported Q3 2024 financial results with revenue of $153.4 million, up 21.4% year-over-year. The company posted a GAAP operating loss of $13.6 million compared to $2.1 million operating income in Q3 2023. Gross profit reached $133.5 million with an 87.1% margin. The company raised its full-year 2024 revenue guidance to $601.5-604.5 million, representing 21.9-22.5% growth over 2023. Inari expects to achieve sustained operating profitability in H1 2025.
Okami Medical has successfully closed a $32.5M financing round led by new investor Vensana Capital and supported by existing investors. The funds will be used to accelerate the development and commercialization of Okami's innovative catheter-based technologies for peripheral vascular occlusion. The company has already developed two key products: the LOBO® Vascular Occlusion System and the SENDERO® Microcatheter.
The LOBO system is designed as a single-device solution for occluding a wide range of peripheral arterial targets, while the SENDERO Microcatheter is optimized for smooth delivery of interventional devices through tortuous peripheral vessels. Both products aim to address shortcomings in traditional vascular occlusion methods, offering more efficient and effective treatment options for various vascular conditions.
Inari Medical (NASDAQ: NARI) announced it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The meeting is scheduled for Tuesday, October 29, 2024, at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time. Interested parties can access the live event via the Events Section of the Inari investor relations website. A replay will be available shortly after the event and archived on the website.
Inari Medical (NASDAQ: NARI) has announced it will release its third quarter 2024 financial results on Monday, October 28, 2024. The company, which focuses on treating venous and other diseases, will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results and recent highlights.
Interested parties can access the earnings call via telephone or webinar. The call-in numbers are 844-825-9789 for domestic callers and 412-317-5180 for international callers. The webinar can be accessed through Inari's investor relations website or by registering online. A replay of the webinar will be available shortly after the call and archived on Inari's website.
